Year All20252024202320222021202020192018201720162015201420122011 Oct 17, 2024 Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024 Oct 15, 2024 Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week Oct 9, 2024 Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology Sep 5, 2024 Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference Aug 8, 2024 Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer Aug 1, 2024 Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update Jul 31, 2024 Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion Jul 18, 2024 Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024 Jul 17, 2024 Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines Jul 2, 2024 To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA